Degenerative disease

Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

Monday, September 20, 2021 - 9:05pm

Please contact your Cantor Fitzgerald representative to schedule virtual one-on-one meetings with Aligos during the conference.

Key Points: 
  • Please contact your Cantor Fitzgerald representative to schedule virtual one-on-one meetings with Aligos during the conference.
  • For more information about the Cantor Virtual Global Healthcare Conference, please refer to the Cantor Fitzgerald conference website .
  • Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Inventiva reports 2021 first half financial results and provides a corporate update

Monday, September 20, 2021 - 9:10pm

Revenues for the first half of 2021 reached 0.1 million, stable compared to the first half of 2020.

Key Points: 
  • Revenues for the first half of 2021 reached 0.1 million, stable compared to the first half of 2020.
  • Net financial income amounted to 0.8 million in the first half of 2021, mainly linked to exchange rate variation.
  • Net cash used in operating activities amounted to 19.8 million and 7.2 million in the first half of 2021 and 2020, respectively.
  • The financial statements of the first half of 2021 were approved by Inventivas Board of Directors on September 16, 2021.

Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference

Monday, September 20, 2021 - 9:01pm

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m.
  • A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.

Richard L. Gordon, DO, is recognized by Continental Who's Who

Monday, September 20, 2021 - 9:06pm

Having led an impressive career for over 50 years, Dr. Richard L. Gordon is a fellowship-trained and board-certified Hematologist specializing in blood disorders and the medical treatment of malignancies.

Key Points: 
  • Having led an impressive career for over 50 years, Dr. Richard L. Gordon is a fellowship-trained and board-certified Hematologist specializing in blood disorders and the medical treatment of malignancies.
  • He is currently seeing patients at Comprehensive Cancer and Hematology Specialists, P.C.
  • Utilizing his extensive medical background, Dr. Gordon is highly committed to providing the best possible care.
  • He has admitting privileges at Virtua Marlton Hospital, Jefferson Stratford Hospital, Jefferson Cherry Hill Hospital, Jefferson Washington Township Hospital, and Virtua Voorhees Hospital.

Solid Biosciences to Participate at Upcoming Investor Conferences

Monday, September 20, 2021 - 9:01pm

A live webcast of managements fireside chat at the Chardan conference will be available on the Companys investor relations website on Tuesday, October 5, 2021 at 2:30 p.m.

Key Points: 
  • A live webcast of managements fireside chat at the Chardan conference will be available on the Companys investor relations website on Tuesday, October 5, 2021 at 2:30 p.m.
  • ET, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events .
  • A replay will be available on the Company's website following the event.
  • Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne.

Phosphorus Receives Conditional Approval from New York State Department of Health for its GeneCompass™ Genetic Test: Available for $249

Monday, September 20, 2021 - 8:30pm

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Phosphorus, a leading preventative genomics company, today announced the receipt of conditional approval from the New York State Department of Health for its GeneCompass genetic test.

Key Points: 
  • NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Phosphorus, a leading preventative genomics company, today announced the receipt of conditional approval from the New York State Department of Health for its GeneCompass genetic test.
  • GeneCompass is the first medical-grade genetic test to cover a broad range of important preventable conditions, not just limited to inherited cancers or cardiovascular disorders.
  • GeneCompass also includes genetics related to endocrinology, vision loss, hearing loss, infertility, neurology, pharmacogenetics and wellness.
  • In addition to the holistic nature of the test, it is available at a price point on par with consumer genetic ancestry tests at $249.

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members

Monday, September 20, 2021 - 7:22pm

Neither Jasper Therapeutics, Inc. nor Amplitude Healthcare Acquisition Corporation gives any assurance that either Jasper Therapeutics, Inc. or Amplitude Healthcare Acquisition Corporation will achieve its expectations.

Key Points: 
  • Neither Jasper Therapeutics, Inc. nor Amplitude Healthcare Acquisition Corporation gives any assurance that either Jasper Therapeutics, Inc. or Amplitude Healthcare Acquisition Corporation will achieve its expectations.
  • In connection with the proposed business combination between Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation, the registration statement on Form S-4 has been declared effective by the SEC.
  • That registration statement includes the related proxy statement and prospectus of Amplitude Healthcare Acquisition Corporation with respect to Amplitude Healthcare Acquisition Corporations special meeting of stockholders.
  • In addition, the documents filed by Amplitude Healthcare Acquisition Corporation may be obtained free of charge by directing a request to Amplitude Healthcare Acquisition Corporation, 1177 Avenue of the Americas, Fl 40, New York, New York 10036.

AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology

Monday, September 20, 2021 - 6:15pm

This abstract has received the honor of being designated as an extended comunicacin oral estelar (stellar oral communication).

Key Points: 
  • This abstract has received the honor of being designated as an extended comunicacin oral estelar (stellar oral communication).
  • We first suspected that masitinib may generate improved survival in certain subgroups through observation of patients enrolled in study AB10015 at the Vall d'Hebron Hospital's ALS Unit [2].
  • 2020;21(1-2):5-14. doi:10.1080/21678421.2019.1632346
    [2] Gamez J. Vall dHebron participates in an international study to validate masitinib for amyotrophic lateral sclerosis treatment.
  • In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy.

Moducare Balances Immunity for Daily Enhanced Support

Monday, September 20, 2021 - 5:33pm

While boosting the immune system sounds like a good plan in an emergency, modulating it makes better sense for a daily routine, which is why Wakunaga of America recommends its Moducare daily immune support supplement to balance and enhance the immune system, while avoiding an overactive immune response.

Key Points: 
  • While boosting the immune system sounds like a good plan in an emergency, modulating it makes better sense for a daily routine, which is why Wakunaga of America recommends its Moducare daily immune support supplement to balance and enhance the immune system, while avoiding an overactive immune response.
  • In one study of marathon runners , the sterols and sterolins used in Moducare were found to help immunity by inhibiting the secretion of pro-inflammatory cytokines and decreasing the stress hormone known as cortisol.
  • Moducare is nontoxic and has no known side effects or drug interactions and is available as a dietary supplement in capsules or chewable tablets.
  • Moducare is the only effective immune modulator that has been researched and clinically tested.

Europe miRNA Sequencing and Assay Market Forecast to 2027: Widening Range of MicroRNA Applications & Rise in Funding for Genomics Research - ResearchAndMarkets.com

Monday, September 20, 2021 - 5:41pm

The "Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.
  • The widening application range of microRNAs and rise in funding for genomics research.
  • Therefore, rise in funding of genomic research to identify new molecules to diagnose and treat diseases, and consequent expansion of the range of applications of miRNAs are driving the growth of the miRNA sequencing and assay market in Europe.
  • Hence, the COVID-19 pandemic has been supporting the Europe miRNA sequencing and assay market growth.